Correlating Differences in the Surface Activity to Interface-Induced Particle Formation in Different Protein Modalities: IgG mAb Versus Fc-Fusion Protein.


Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
07 Oct 2024
Historique:
medline: 7 10 2024
pubmed: 7 10 2024
entrez: 7 10 2024
Statut: ppublish

Résumé

The propensity of protein-based biologics to form protein particles during bioprocessing can be related to their interfacial properties. In this study, we compare the surface activity and interfacial film properties of two structurally different biologics, an IgG and Fc-fusion, in the absence and presence of interfacial dilatational stresses, and correlate these differences to their tendency to form interface-induced protein particles. Our results show that interface-induced particle formation is protein-dependent, with the Fc-fusion demonstrating greater interfacial stability. This observation can be correlated with faster adsorption kinetics of the Fc-fusion protein, and formation of a less incompressible film at the air-liquid interface. The addition of polysorbate 80 (PS80), commonly added to mitigate protein particle formation, led to a surfactant-dominant interface for quiescent conditions and coadsorption of protein and surfactant for the Fc-fusion when exposed to interfacial stress. On the other hand, for the IgG molecule, the surface always remained surfactant dominant. Image analysis demonstrated that PS80 was more effective in mitigating particle formation for the IgG than Fc-fusion. This suggests that a surfactant-dominant interface is necessary to prevent interface-induced protein particle formation. Further, while PS80 is effective in mitigating particle formation in the IgG formulation, it may not be the best choice for other protein modalities.

Identifiants

pubmed: 39370821
doi: 10.1021/acs.molpharmaceut.4c00488
doi:

Substances chimiques

Immunoglobulin G 0
Immunoglobulin Fc Fragments 0
Polysorbates 0
Surface-Active Agents 0
Antibodies, Monoclonal 0
Recombinant Fusion Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5088-5103

Auteurs

Valerie P Griffin (VP)

Department of Chemical and Petroleum Engineering, The University of Kansas, 1530 W 15th Street, Lawrence, Kansas 66045, United States.

Estephanie L N Escobar (ELN)

Department of Chemical and Petroleum Engineering, The University of Kansas, 1530 W 15th Street, Lawrence, Kansas 66045, United States.

Maria O Ogunyankin (MO)

Drug Product Development, Bristol Myers Squibb, New Brunswick, New Jersey 08901, United States.

Ankit Kanthe (A)

Drug Product Development, Bristol Myers Squibb, New Brunswick, New Jersey 08901, United States.

Madhushree Gokhale (M)

Drug Product Development, Bristol Myers Squibb, New Brunswick, New Jersey 08901, United States.

Prajnaparamita Dhar (P)

Department of Chemical and Petroleum Engineering, The University of Kansas, 1530 W 15th Street, Lawrence, Kansas 66045, United States.

Articles similaires

Humans COVID-19 Immunoglobulin G Antibodies, Viral SARS-CoV-2
1.00
Immunoconjugates Humans Antibodies, Bispecific Receptor, ErbB-2 Cell Line, Tumor

Characterization of 3D printed composite for final dental restorations.

Lucas Eigi Borges Tanaka, Camila da Silva Rodrigues, Manassés Tércio Vieira Grangeiro et al.
1.00
Composite Resins Materials Testing Printing, Three-Dimensional Surface Properties Flexural Strength
Humans Amyotrophic Lateral Sclerosis Male Middle Aged Female

Classifications MeSH